Comparative Pharmacology
Head-to-head clinical analysis: DOXERCALCIFEROL versus ROCALTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXERCALCIFEROL versus ROCALTROL.
DOXERCALCIFEROL vs ROCALTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxercalciferol is a synthetic vitamin D2 analog that undergoes hepatic conversion to its active metabolite, 1α,25-dihydroxyvitamin D2, which binds to the vitamin D receptor (VDR) in the parathyroid glands, reducing parathyroid hormone (PTH) synthesis and secretion. It also increases intestinal calcium and phosphate absorption and promotes bone mineralization.
Calcitriol, the active form of vitamin D, binds to vitamin D receptors in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone mineralization.
0.5 mcg orally three times per week at each hemodialysis session; alternatively, 1 mcg orally three times per week. Intravenous: 0.5 mcg bolus three times per week at end of hemodialysis; titrate to target intact parathyroid hormone (iPTH) level.
Oral, 0.25 mcg once daily; may increase to 0.5 mcg once daily based on response. Typical adult dose is 0.25-0.5 mcg/day.
None Documented
None Documented
Clinical Note
moderateDoxercalciferol + Hydrochlorothiazide
"Doxercalciferol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateDoxercalciferol + Bendroflumethiazide
"Doxercalciferol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateDoxercalciferol + Methyclothiazide
"Doxercalciferol may increase the hypercalcemic activities of Methyclothiazide."
Clinical Note
moderateDoxercalciferol + Hydroflumethiazide
Terminal elimination half-life is approximately 96 hours (range 48–168 hours) in patients with chronic kidney disease, reflecting slow release from adipose tissue and prolonged vitamin D receptor activation.
Terminal elimination half-life is approximately 25–35 hours after oral administration. Clinical context: Once-weekly or thrice-weekly dosing achieves steady state in 1–2 weeks.
Primarily fecal (biliary) elimination; renal excretion accounts for <2% of unchanged drug in urine.
Primarily biliary/fecal; approximately 50% of dose recovered in feces within 24 hours. Renal excretion accounts for <5% of unchanged drug.
Category A/B
Category C
Vitamin D Analog
Vitamin D Analog
"Doxercalciferol may increase the hypercalcemic activities of Hydroflumethiazide."